# Aldeyra Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Aldeyra Therapeutics, Inc.). ## Overview Aldeyra Therapeutics is a clinical-stage biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its lead programs center on RASP (reactive aldehyde species) modulators, including reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation being studied for retinal and vitreoretinal disorders. The company also has earlier-stage RASP-modulating candidates such as ADX-248 and ADX-246 aimed at systemic and retinal immune-mediated diseases. Aldeyra has no approved products and is still dependent on clinical progress, regulatory outcomes, and future partnering to create commercial revenue. ## Products & services • Reproxalap for dry eye disease • Reproxalap for allergic conjunctivitis • ADX-2191 intravitreal methotrexate • ADX-248 RASP modulator • ADX-246 RASP modulator • Other immune-modulating pipeline candidates - **Late-stage ophthalmology candidates** (60%) — Clinical-stage eye-disease programs focused on dry eye disease, allergic conjunctivitis, and retinal indications. - **RASP-modulating small molecules** (25%) — Compounds designed to modulate reactive aldehyde species and broader immune pathways. - **Intravitreal oncology/retinal formulations** (15%) — Specialty ophthalmic formulations such as ADX-2191 for vitreoretinal lymphoma and related retinal disorders. - Reproxalap, a RASP modulator for dry eye disease - Reproxalap for allergic conjunctivitis - ADX-2191, a novel intravitreal methotrexate formulation - ADX-2191 development for primary vitreoretinal lymphoma - ADX-2191 development for retinitis pigmentosa - ADX-248 and ADX-246, earlier-stage RASP modulators - Additional chemically related immune-modulating molecules ## Customers Aldeyra does not currently sell approved products, so its near-term 'customers' are primarily regulators, clinical investigators, and potential development partners rather than end users. If reproxalap or another candidate is approved, the commercial customer base would likely include ophthalmologists, retina specialists, and other prescribers treating inflammatory eye disease. For ADX-2191, the relevant end users would be specialists treating rare retinal and vitreoretinal conditions in clinical or specialty-care settings. The company also targets pharmaceutical partners that could help fund development or commercialize approved products, which is important because Aldeyra has stated it may commercialize through collaborations. - **Ophthalmology prescribers** (primary) — Eye-care physicians who would prescribe reproxalap if approved for dry eye disease or allergic conjunctivitis. - **Retina and vitreoretinal specialists** (primary) — Specialists who would use ADX-2191 in rare retinal or vitreoretinal indications if approved. - **Pharmaceutical partners** (primary) — Potential collaborators that may fund, develop, or commercialize the company's product candidates. - **Clinical trial ecosystem** (secondary) — Investigative sites, CROs, and investigators that conduct studies needed for regulatory approval. - Ophthalmologists treating dry eye disease and allergic conjunctivitis - Retina specialists treating rare vitreoretinal disorders - Oncology/ocular specialists treating primary vitreoretinal lymphoma - Patients with immune-mediated eye disease and limited treatment options - Potential pharma partners for commercialization and co-development - Clinical investigators and trial sites supporting development programs ## Geography Aldeyra is headquartered in Lexington, Massachusetts and is incorporated in Delaware, with operations centered in the United States. The company has indicated that reproxalap may require clinical activities and regulatory review outside the United States as well, which suggests some international development exposure even before commercialization. Because it has no approved products, current geographic exposure is driven mainly by where trials are run, where regulators are engaged, and where future partners may be located. If approved, the company would likely commercialize through a partner or direct channel in major ophthalmology markets, but no country-level revenue is currently disclosed. - Headquartered in Lexington, Massachusetts, United States - Incorporated in Delaware and managed from the U.S. - Clinical and regulatory activity may extend outside the United States - No approved-product revenue by country is currently disclosed - Future commercialization could involve U.S. and ex-U.S. partners - Geographic exposure is mainly trial, regulatory, and partnering related ## Strategy Aldeyra's strategy is to advance reproxalap and ADX-2191 through late-stage development and secure regulatory approval for at least one lead asset. The company is also broadening its pipeline with additional RASP-modulating and immune-modulating candidates, which is intended to reduce dependence on a single program. Management has stated that commercialization would likely occur through a collaboration, reflecting the company's lack of in-house sales infrastructure and its need to conserve capital. In parallel, Aldeyra continues to evaluate in-licensing or acquisition opportunities that fit its immune-mediated disease focus and could add value if development risk is manageable. - **Secure approval path for reproxalap** (short-term) — The company's future value is heavily dependent on whether its lead dry-eye asset can clear regulatory hurdles and reach market. - **Partner for commercialization** (short-term) — Aldeyra has no commercial organization and expects to rely on third parties to market approved products. - **Broaden the immune-modulating pipeline** (medium-term) — Pipeline diversification can reduce single-asset dependence and create additional shots on goal. - Advance reproxalap toward regulatory approval - Pursue ADX-2191 in selected retinal and vitreoretinal indications - Expand the pipeline with new immune-modulating candidates - Use partnerships for commercialization rather than building a large sales force - Evaluate in-licensing or acquisition of complementary assets - Preserve capital while prioritizing programs with feasible regulatory paths ## Risks Aldeyra's most important risk is that reproxalap may not receive approval, may face delays, or may fail commercially even if approved, which would materially impair the business. The company also depends on third parties for clinical trials and likely for future commercialization, so execution failures by CROs, investigators, or partners could delay development and increase costs. As a clinical-stage biotech with no approved products, Aldeyra faces substantial financing risk because it must raise additional capital to fund trials, manufacturing scale-up, and commercialization preparation. More broadly, the company is exposed to intense biotechnology competition, regulatory uncertainty in the U.S. and abroad, and the possibility that prior clinical signals will not be replicated in later studies. - **Dependence on reproxalap** [high] — The company states that its business is dependent in large part on successful commercialization of reproxalap. - **Regulatory approval uncertainty** [high] — The FDA has already issued a Complete Response Letter for ADX-2191, showing that approval outcomes are uncertain and can require additional evidence. - **Need for additional financing** [high] — The company has no product revenue and will need capital to continue development and prepare for commercialization. - **Third-party trial execution** [medium] — Clinical trials are conducted with external sites and partners, creating schedule and quality control risk. - **Competitive pressure in ophthalmology and immunology** [medium] — Competitors may develop more effective or safer therapies, reducing the addressable market for Aldeyra's candidates. - Reproxalap regulatory failure or delay could materially harm the company - Commercialization may fail even if approval is obtained - Additional financing will likely be needed to fund development - Third-party CRO or partner underperformance can delay trials - Clinical data may not replicate in later-stage studies - Competition may produce safer or more effective therapies - Regulatory requirements may change in the U.S. or abroad - Public health or macro disruptions can affect trial execution ## Accounting Aldeyra is a pre-revenue biotech, so its financial statements are dominated by research and development expense accruals rather than product revenue recognition. A key judgment area is accrued and deferred R&D expense, where management estimates costs for clinical sites, contract manufacturers, and consultants before invoices are received; this can materially affect quarterly expense timing. Because the company has no approved products, there is no meaningful commercial revenue recognition complexity yet, but future licensing or collaboration arrangements could introduce milestone, royalty, or deferred revenue judgments. Investors should also watch for fair-value and debt-related accounting, since the company has funded operations through equity, convertible instruments, warrants, and borrowings, and these instruments can create non-cash volatility in reported results. - **Accrued and deferred research and development expenses** — Affects reported operating loss and quarterly comparability - **Future collaboration and license accounting** — Could affect future revenue timing and deferred revenue balances - **Equity and convertible financing instruments** — Can affect non-cash charges, EPS dilution, and balance sheet presentation - Accrued and deferred R&D expenses affect quarterly operating loss timing - Clinical site and CRO invoices may arrive after services are performed - Contract manufacturing and preclinical costs require estimation - Future collaboration revenue could involve milestone and license accounting - Equity-linked financing may create non-cash accounting volatility - Interest expense and debt accounting matter because the company uses external funding --- *Last updated: 2026-08-11T04:46:19.900098+00:00*